1-6 of 6
Gregory A. Wiseman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Izel Okcu, Arushi Khurana, Urshila Durani, Robert J. Levy, Muhamad Alhaj Moustafa, Allison C. Rosenthal, Robert Delaune, Daniel P. Larson, Thomas E. Witzig, Matthew T. Howard, Gregory A. Wiseman, Madiha Iqbal, Nneka I. Comfere, Namrata Shah, Lawrence Breitkreutz, Mike S. Bold, Yucai Wang, Brendan W. Lunn, Scott C. Lester, William G. Breen, Bradford S Hoppe, Caroline R. Hill, Valerie M. Kimball, Adrienne N. Nedved, Ruth A. Lentz, Rebecca L. King, Thomas M. Habermann
Journal: Blood
Blood (2024) 144 (Supplement 1): 2283.
https://doi.org/10.1182/blood-2024-210539
Published: 2024
Journal Articles

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Clinical Trials & Observations
Wei Ding, Betsy R. LaPlant, Timothy G. Call, Sameer A. Parikh, Jose F. Leis, Rong He, Tait D. Shanafelt, Sutapa Sinha, Jennifer Le-Rademacher, Andrew L. Feldman, Thomas M. Habermann, Thomas E. Witzig, Gregory A. Wiseman, Yi Lin, Erik Asmus, Grzegorz S. Nowakowski, Michael J. Conte, Deborah A. Bowen, Casey N. Aitken, Daniel L. Van Dyke, Patricia T. Greipp, Xin Liu, Xiaosheng Wu, Henan Zhang, Charla R. Secreto, Shulan Tian, Esteban Braggio, Linda E. Wellik, Ivana Micallef, David S. Viswanatha, Huihuang Yan, Asher A. Chanan-Khan, Neil E. Kay, Haidong Dong, Stephen M. Ansell
Journal: Blood
Blood (2017) 129 (26): 3419–3427.
https://doi.org/10.1182/blood-2017-02-765685
Published: 2017
Includes: Supplemental data
Journal Articles

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Clinical Trials & Observations
Ivana N. M. Micallef, Matthew J. Maurer, Gregory A. Wiseman, Daniel A. Nikcevich, Paul J. Kurtin, Michael W. Cannon, Domingo G. Perez, Gamini S. Soori, Brian K. Link, Thomas M. Habermann, Thomas E. Witzig
Journal: Blood
Blood (2011) 118 (15): 4053–4061.
https://doi.org/10.1182/blood-2011-02-336990
Published: 2011
Journal Articles

A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).

Thomas E. Witzig, MD, Gregory A. Wiseman, MD, George Weiner, MD, Stephen M. Ansell, MD, PHD, Ivana Micallef, MD, Thomas M. Habermann, MD, Clive S. Zent, MD, David J. Inwards, MD, Tait Shanafelt, MD, Luis Porrata, MD, Matthew J. Maurer, MS, Cristine Allmer, Zuhair Ballas, MD
Journal: Blood
Blood (2007) 110 (11): 124.
https://doi.org/10.1182/blood.V110.11.124.124
Published: 2007
Journal Articles

FDG PET Scan Alone Better Predicts Progression Free Survival at 2 Years Compared to CT Imaging in Aggressive Histology Non-Hodgkin’s Lymphoma Following Initial Anthracycline-Based Chemotherapy.

Gregory A. Wiseman, MD, Malik E. Juweid, MD, Eric M. Rohren, MD, PhD, James E. Wooldridge, MD, Michael M. Graham, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 3299.
https://doi.org/10.1182/blood.V104.11.3299.3299
Published: 2004
Journal Articles

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Clinical Trials & Observations
Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani, Thomas E. Witzig, Stewart Spies, Nancy L. Bartlett, Russell J. Schilder, James L. Murray, Mansoor Saleh, Roberta S. Allen, Antonio J. Grillo-López, Christine A. White
Journal: Blood
Blood (2002) 99 (12): 4336–4342.
https://doi.org/10.1182/blood.V99.12.4336
Published: 2002